The EVICEL® Neurosurgery Phase III Study

PHASE3CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

September 13, 2017

Study Completion Date

October 12, 2017

Conditions
Cerebrospinal Fluid Leak
Interventions
BIOLOGICAL

EVICEL Fibrin Sealant

DEVICE

Hydrogel sealant

Trial Locations (26)

1023

Clinical Investigation Site #53, Auckland

2109

Clinical Investigation Site #51, Sydney

3121

Clinical Investigation Site #52, Richmond

5000

Clinical Investigation Site #54, Adelaide

10065

Clinical Investigation Site #12, New York

19107

Clinical Investigation Site #21, Philadelphia

21201

Clinical Investigation Site #15, Baltimore

32207

Clinical Investigation Site #18, Jacksonville

33606

Clinical Investigation Site #19, Tampa

45219

Clinical Investigation Site #14, Cincinnati

46202

Clinical Investigation Site #22, Indianapolis

48109

Clinical Investigation Site #24, Ann Arbor

70121

Clinical Investigation Site #10, New Orleans

90033

Clinical Investigation Site #27, Los Angeles

95817

Clinical Investigation Site #17, Sacramento

02215

Clinical Investigation Site #11, Boston

08903

Clinical Investigation Site #20, New Brunswick

Unknown

Clinical Investigation Site #50, Melbourne

Clinical Investigation Site #40, Genk

Clinical Investigation Site #41, Leuven

Clinical Investigation Site #35, London

Clinical Investigation Site #32, Middlesbrough

Clinical Investigation Site #35, Nottingham

Clinical Investigation Site #30, Oxford

Clinical Investigation Site #31, Salford

H3A 2B4

Clinical Investigation Site #25, Montreal

All Listed Sponsors
lead

Ethicon, Inc.

INDUSTRY

NCT02457546 - The EVICEL® Neurosurgery Phase III Study | Biotech Hunter | Biotech Hunter